Automated Insulin Delivery Technology Receives FDA Clearance for Individuals With Type 2 Diabetes

A next generation automated insulin delivery (AID) algorithm, Control-IQ+ technology (Control-IQ+; Tandem Diabetes Care, Inc.) received FDA clearance for use among individuals aged 18 years and older with type 2 diabetes. The current indication expands on the previous Control-IQ+ clearance for use by individuals with type 1 diabetes.

“Type 2 diabetes affects millions of Americans and increases the risk of serious health conditions, including heart disease, stroke, kidney disease, and nerve damage, reinforcing the importance of consistent management of blood sugar," Jordan Pinsker, MD, chief medical officer, said in a news release.